Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024 – By Product Type (Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza), By Route Of Administration (Oral, Injection, Inhalation), By End User (Hospitals, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024

Starting Price : $5000.00 | Pages : 175 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs
Customise Your Report
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying
Alpha 1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Definition And Segments

Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients.

The main types of products in alpha-1 antitrypsin deficiency augmentation therapy are glassia, aralast NP, prolastin C, zemaira and respreeza. Glassia is a medicine containing human Alpha1-Proteinase inhibitors (Alpha1-PI). It is used to treat adults with lung disease (emphysema) caused by severe alpha1-antitrypsin (Alpha1) deficiency. They are administered through oral, injection and inhalations by hospitals, specialty clinics and others.

The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –

1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza

2) By Route Of Administration: Oral, Injection, Inhalation

3) By End User: Hospitals, Specialty Clinics, Other End Users

The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.

The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.

Impact Of Rising Respiratory Disease Prevalence On The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

An increase in the number of respiratory diseases is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. Respiratory diseases are disorders that affect the lungs and the respiratory system, leading to breathing difficulties and impaired lung function. Alpha-1 antitrypsin deficiency augmentation therapy aims to treat respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. The therapy works by restoring the balance of protease-antiprotease activity in the lungs, protecting lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the increase in the number of respiratory diseases propels the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Increase In The Number Of Clinical Trials Is Anticipated To Boost The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

The increase in the number of clinical trials is expected to propel the growth of the alpha-1 antitrypsin deficiency augmentation therapy market going forward. A clinical trial refers to a biomedical or behavioral research study conducted on human participants to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials are essential for the development and approval of new therapies and drugs for the treatment of AATD. The increase in the number of clinical trials indicates that there is a growing interest in the development of new therapies for AATD, which can lead to the introduction of new and more effective treatments in the market. For instance, in May 2023, according to a report published by Xtalks, a Canada-based web news and information network, there are 452,604 clinical studies that have been registered on ClinicalTrials.gov as of May 2023. This marks a significant rise from the more than 365,000 registered trials that were recorded in early 2021. Therefore, the increase in the number of clinical trials is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Major players in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

Limited Approved Medications Hinder The Market

Limitedly approved medications are anticipated to be the restraint that may impact the growth of the alpha-1 antitrypsin deficiency augmentation therapy market in the future. The availability of approved medications is limited, which can limit the treatment options available to patients and healthcare providers. Augmentation therapy with purified intravenous alpha-1 antitrypsin is the only currently approved treatment for AATD. For instance, according to the COPD Foundation, a US-based nonprofit organization, Annual medical expenses for people with AATD are $127,537 for augmentation treatment users and $15,874 for non-users, with 75.3% of patients utilizing augmentation therapy. Therefore, limited approved medications are restraining the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Innovative Recombinant Technology-Based Drug Development Shaping The Ards Market

Major companies operating in the acute respiratory distress syndrome (ARDS) market are focusing on developing innovative therapies, such as recombinant technology-based drug development, to sustain their position in the market. The recombinant DNA technology is used to manufacture therapeutic pharmaceuticals recombinant technology-based drug development. This method includes modifying the DNA of live organisms to synthesize specific proteins. For instance, in March 2022, Inhibrx Inc., a US-based biotechnology company, announced that INBRX-101 had received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein with the potential for a once-monthly dosage. It is intended to safely achieve and maintain levels of AAT found in healthy individuals.

Glaxosmithkline Enhances Oligonucleotide Therapeutics Portfolio Through Investment In Wave Life Sciences

In January 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company, acquired an 11% Stake in Wave Life Sciences Ltd. for $50 million. This acquisition aims to capitalize on GSK's expertise in human genetics, worldwide development and commercial capabilities in conjunction with Wave's exclusive discovery and drug development platform, PRISMTM. The aim is to accelerate the progress of oligonucleotide therapeutics for genetically determined diseases. Wave Life Sciences Ltd. is a US-based clinical-stage RNA medicine company, including the development of drug for Alpha-1 Antitrypsin Deficiency (AATD).

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2023. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alpha-1 antitrypsin deficiency augmentation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alpha-1 antitrypsin deficiency augmentation therapy market consists of sales of Fazirsiran and RNA interference (RNAi) therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The alpha-1 antitrypsin deficiency augmentation therapy market research report is one of a series of new reports from The Business Research Company that provides alpha-1 antitrypsin deficiency augmentation therapy market statistics, including alpha-1 antitrypsin deficiency augmentation therapy industry global market size, regional shares, competitors with an alpha-1 antitrypsin deficiency augmentation therapy market share, detailed alpha-1 antitrypsin deficiency augmentation therapy market segments, market trends and opportunities and any further data you may need to thrive in the alpha-1 antitrypsin deficiency augmentation therapy industry. This alpha-1 antitrypsin deficiency augmentation therapy market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $1.69 billion
Revenue Forecast In 2033 $2.26 billion
Growth Rate CAGR of 7.5% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Pfizer Inc.; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Amgen Inc.; Baxter International Inc.; CSL Limited; Biogen Inc.; Vertex Pharmaceuticals Incorporated; Grifols S.A.; BioMarin Pharmaceutical Inc.; LFB Group; Octapharma AG; Arrowhead Pharmaceuticals Inc.; Kamada Ltd.; Krystal Biotech Inc.; Intellia Therapeutics Inc.; Mereo BioPharma Group PLC; Protalix BioTherapeutics Inc.; Centessa Pharmaceuticals Limited; Inhibrx Inc.; Liminal BioSciences Inc.; Applied Genetic Technologies Corporation; Abeona Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Characteristics

    3. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends And Strategies

    4. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Growth

    5.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segmentation

    6.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Glassia

    Aralast NP

    Prolastin C

    Zemaira And Respreeza

    6.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Injection

    Inhalation

    6.3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Specialty Clinics

    Other End Users

    7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Regional And Country Analysis

    7.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    8.1. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    9.1. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview  

    9.2. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    10.1. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    11.1. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview  

    11.2. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    12.1. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    13.1. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    14.1. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview  

    14.2. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    15.1. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    15.2. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    16.1. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    17.1. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    18.5. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    19.9. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    20.13. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    21.1. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    21.2. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    22.1. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    23.1. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    23.2. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    24.1. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    24.2. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    25.1. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    25.2. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    26.1. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    26.2. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    27.1. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    28.1. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    28.2. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market  

    29.1. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview

    29.2. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Landscape And Company Profiles

    30.1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Landscape

    30.2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Sanofi S.A.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. AstraZeneca plc

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. GlaxoSmithKline plc

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Takeda Pharmaceutical Company Limited

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Other Major And Innovative Companies

    31.1. Amgen Inc.

    31.2. Baxter International Inc.

    31.3. CSL Limited

    31.4. Biogen Inc.

    31.5. Vertex Pharmaceuticals Incorporated

    31.6. Grifols S.A.

    31.7. BioMarin Pharmaceutical Inc.

    31.8. LFB Group

    31.9. Octapharma AG

    31.10. Arrowhead Pharmaceuticals Inc.

    31.11. Kamada Ltd.

    31.12. Krystal Biotech Inc.

    31.13. Intellia Therapeutics Inc.

    31.14. Mereo BioPharma Group PLC

    31.15. Protalix BioTherapeutics Inc.

    32. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Benchmarking

    33. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

    35. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Future Outlook and Potential Analysis

    35.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2028 - Countries Offering Most New Opportunities

    35.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2028 - Segments Offering Most New Opportunities

    35.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Pfizer Inc. Financial Performance
  • Table 75: Sanofi S.A. Financial Performance
  • Table 76: AstraZeneca plc Financial Performance
  • Table 77: GlaxoSmithKline plc Financial Performance
  • Table 78: Takeda Pharmaceutical Company Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Pfizer Inc. Financial Performance
  • Figure 75: Sanofi S.A. Financial Performance
  • Figure 76: AstraZeneca plc Financial Performance
  • Figure 77: GlaxoSmithKline plc Financial Performance
  • Figure 78: Takeda Pharmaceutical Company Limited Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
TNF Alpha Inhibitors Global Market Report 2024 – By Drug (Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)), By Route Of Administration (Oral, Subcutaneous, Intravenous, Other Route Of Administration), By Disease Type (Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types) – Market Size, Trends, And Global Forecast 2024-2033
View Report
5-Alpha Reductase Deficiency Global Market Report 2024 – By Diagnosis (Chromosome Analysis, Gene Sequencing, Hormone Tests, Imaging Tests, Genetic Screening, Other Diagnosis), By Treatment (Surgery, Vaginoplasty, Feminizing Genitoplasty, Hormone Replacement Therapy, Other Treatments), By End-Users (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Alpha Glucosidase Inhibitors Global Market Report 2024 – By Type (Dumping Syndrome, Type 2 Diabetes), By Drug class (Acarbose, Miglitol, Voglibose), By Constituent (Glucoamylase, Isomaltase, Maltase, Sucrase), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Devices And Equipment (Therapeutic And Diagnostic) Global Market Report 2024 – By Type (Diagnostic devices, Therapeutic devices, Monitoring devices), By Therapeutic Devices (Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators, Other Therapeutic Devices), By Diagnostic Devices (Spirometer, Polysomnographs, Peak Flow Meters), By Monitoring Devices (Pulse oximeters, Capnographs, Gas analyzers), By Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distress Syndrome (RDS), Cystic Fibrosis, Pneumonia), By End User (Hospitals, Clinics, Homecare settings, Ambulatory service centers,) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Disposables Global Market Report 2024 – By Type (Masks, Tubes, Inhalers, Other Types), By Disease Indications (Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respiratory Diseases), By Application (Adult, Pediatric & Neonatal), By End User (Hospitals, Clinics, Ambulatory Care Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024 – By Product (Instruments And Devices, Assays And Reagents), By Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests), By Disease Type (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases), By End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024 – By Product (Nebulizers, Humidifiers, Oxygen Concentrators, Positive Airway Pressure Devices, Ventilators, Capnographs, Gas Analyzers), By Technology (HEPA Filter, Electrostatic Filtration, Microsphere Separation, Hollow Fiber Filtration, Other Technologies), By End-User (Homecare settings, Hospitals) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Respiratory Monitoring Devices Global Market Report 2024 – By Type (Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs, Others Types), By Application (Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma, Other Applications), By End-User (Laboratories, Hospitals, Home Use) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the alpha-1 antitrypsin deficiency augmentation therapy market?

Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients. request a sample here

How will the alpha-1 antitrypsin deficiency augmentation therapy market drivers and restraints affect the alpha-1 antitrypsin deficiency augmentation therapy market dynamics? What forces will shape the alpha-1 antitrypsin deficiency augmentation therapy industry going forward?

The alpha-1 antitrypsin deficiency augmentation therapy market major growth driver - Impact Of Rising Respiratory Disease Prevalence On The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market. request a sample here

What is the forecast market size or the forecast market value of the alpha-1 antitrypsin deficiency augmentation therapy market?

The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population. The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens. request a sample here

How is the alpha-1 antitrypsin deficiency augmentation therapy market segmented?

The alpha-1 antitrypsin deficiency augmentation therapy market is segmented
1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End UsersFor further insights on the alpha-1 antitrypsin deficiency augmentation therapy market request a sample here

Which region has the largest share of the alpha-1 antitrypsin deficiency augmentation therapy market? What are the other regions covered in the report?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2023. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. request a sample here.

Who are the major players in the alpha-1 antitrypsin deficiency augmentation therapy market?

Major players in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc. request a sample here.

What are the key trends in the alpha-1 antitrypsin deficiency augmentation therapy market?

Major trend in the alpha-1 antitrypsin deficiency augmentation therapy market - Innovative Recombinant Technology-Based Drug Development Shaping The Ards Market. request a sample here.

What are the major opportunities in the alpha-1 antitrypsin deficiency augmentation therapy market? What are the strategies for the alpha-1 antitrypsin deficiency augmentation therapy market?

For detailed insights on the major opportunities and strategies in the alpha-1 antitrypsin deficiency augmentation therapy market, request a sample here.

How does the alpha-1 antitrypsin deficiency augmentation therapy market relate to the overall economy and other similar markets?

For detailed insights on alpha-1 antitrypsin deficiency augmentation therapy market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the alpha-1 antitrypsin deficiency augmentation therapy industry?

For detailed insights on the mergers and acquisitions in the alpha-1 antitrypsin deficiency augmentation therapy industry, request a sample here.

What are the key dynamics influencing the alpha-1 antitrypsin deficiency augmentation therapy market growth? SWOT analysis of the alpha-1 antitrypsin deficiency augmentation therapy market.

For detailed insights on the key dynamics influencing the alpha-1 antitrypsin deficiency augmentation therapy market growth and SWOT analysis of the alpha-1 antitrypsin deficiency augmentation therapy industry, request a sample here.